Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
Rezera has aligned with regulators on trial design of Phase 3 study of ruvonoflast in peripheral artery disease (PAD), expected to initiate in 1H of
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
Rezera plans to advance ruvonoflast into a Phase 3 clinical trial in peripheral artery disease (PAD) in H1 of 2027 Boston, MA, September 9, 2026
NodThera to Participate in Cantor Global Healthcare Conference
Boston, MA, September 2, 2026 – NodThera, a leading clinical-stage company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers
EPIDAREX ANNOUNCES LEADERSHIP APPOINTMENTS
With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
Round includes participation from Medtronic and top healthcare investors MIAMI, July 16, 2026 (GLOBE NEWSWIRE) — RapidPulse, Inc., a medical technology company developing next-generation aspiration
NodThera Announces the Publication and Presentation of Cardiometabolic Clinical DataSupporting the Potential of Ruvonoflast to Treat Inflammation at the Source
Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk markers with
NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress
Boston, MA, May 19, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory
Nyra Medical to Highlight First-in-Human Clinical Insights Through Three Presentations at EuroPCR
ATLANTA, May 14, 2026 /PRNewswire/ — Nyra Medical, a leading innovator in structural heart therapies, today announced its participation in the upcoming EuroPCR meeting, where the company